Portfolio company IMBiologics completed IPO on Kosdaq, raising 52.0 billion KRW with 839:1 institutional oversubscription.
IMBiologics is a biotech company focused on developing innovative antibody therapeutics for autoimmune diseases and cancer using its proprietary platform, IM-OpDECon
IMBiologics is a biotech company focused on developing innovative antibody therapeutics for autoimmune diseases and cancer using its proprietary platform, IM-OpDECon.